Naproxen oral suspension ( DrugBank: Naproxen )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
46悪性関節リウマチ2

46. 悪性関節リウマチ


臨床試験数 : 4,325 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 185 - 標的パスウェイ数 : 223
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00034853
(ClinicalTrials.gov)
December 20002/5/2002Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid ArthritisArthritis, Juvenile RheumatoidDrug: meloxicam oral suspension;Drug: naproxen oral suspensionBoehringer IngelheimNULLCompleted2 Years17 YearsBoth180Phase 3United States;Brazil;Mexico;Ukraine;Argentina
2NCT00279747
(ClinicalTrials.gov)
September 200019/1/2006A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.Arthritis, Juvenile RheumatoidDrug: meloxicam 0.25 mg/kg;Drug: meloxicam 0.125 mg/kg;Drug: naproxen 10 mg/kgBoehringer IngelheimNULLCompleted2 Years16 YearsBoth226Phase 3Austria;Belgium;France;Germany;Italy;Russian Federation;United Kingdom